Albuquerque, NM
Ketamine Therapy clinics in Albuquerque
Albuquerque has multiple clinics offering ketamine therapy, a fast growing segment for treatment resistant depression, PTSD, chronic pain, and anxiety. New Mexico has limited ketamine clinics but permits telehealth for non controlled medications; ketamine itself requires in person or DEA compliant workflow. Most Albuquerque clinics deliver IV ketamine infusions in a monitored clinical setting, typically across a 6 session induction protocol, followed by maintenance infusions. Spravato (esketamine), the FDA approved nasal spray for treatment resistant depression, is available in Albuquerque only at REMS certified clinics and is often covered by insurance when medical necessity is documented. Compounded ketamine lozenges and troches are also prescribed in Albuquerque, sometimes through telehealth platforms like Mindbloom, Joyous, and Innerwell, subject to Ryan Haight Act and DEA special registration considerations. Local pricing in Albuquerque sits in the affordable range: single IV infusions run 400 to 700 dollars, a full 6 session protocol lands at 2,400 to 4,200, and Spravato copays depend on insurance coverage. A reputable Albuquerque ketamine clinic will pair pharmacology with integration support, monitor vitals during infusion, and have a clear crisis and follow up plan.
Spectrum Health Hub
- Biofeedback Therapy
- Transcranial Magnetic Stimulation (TMS)
- Neurofeedback Therapy
- Ketamine Therapy
Regulatory context
A note on New Mexico's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
Medical Psilocybin Act / SB 219 (2025)
Signed April 2025, establishing a state medical psilocybin program for qualifying conditions (treatment-resistant depression, PTSD, substance use disorder, end-of-life care); implementation rulemaking underway through the NM Department of Health. -
New Mexico Controlled Substances Act
Mirrors federal scheduling outside the medical psilocybin program.
New Mexico enforces federal scheduling outside the medical psilocybin program. The New Mexico Medical Board oversees prescriber conduct. DEA enforcement on ketamine clinics focuses on diversion and Ryan Haight Act telehealth rules. The Medical Psilocybin Act requires rulemaking by the New Mexico Department of Health and creates a state-licensed medical program with physician oversight distinct from Oregon's facilitator model and Colorado's healing center model.